Results 241 to 250 of about 51,902 (295)

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang, Nicolaas P. A. Zuithoff, Inge M. Haeck, Veroniek E. M. Harbers, Simone Stadhouders‐Keet, Klaziena Politiek, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Hoo‐Yin Lam, Anne‐Moon van Tuyll van Serooskerken, Shiarra M. Stewart, Antoni Gostynski, Annebeth Flinterman, Berit Velstra, Wouter R. H. Touwslager, Francine C. van Erp, Marie L. A. Schuttelaar, Marjolein S. de Bruin‐Weller, Marlies de Graaf   +18 more
wiley   +1 more source

Molecular basis and cellular effects of Janus-class-driven cytoplasmic PYK2 coacervates. [PDF]

Commun Biol
Colombo G, Salem I, Szczepski K, Yu P, Alfaiyz S, Guzmán-Vega FJ, Abogosh A, Kulmanov M, Al-Harthi S, Kadaré G, Hoehndorf R, Girault JA, Jaremko Ł, Momin AA, Arold ST.   +14 more
europepmc   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Signaling pathways in systemic lupus erythematosus and therapeutic implications. [PDF]

Front Immunol
Balogh L, Kovács VG, Nagy G, Németh T.
europepmc   +1 more source

The Janus framework of the integrated stress response: from homeostasis to maladaptation. [PDF]

Life Sci Alliance
Altintas DM, Cerqua M, Comoglio PM, Chaveroux C.   +3 more
europepmc   +1 more source

Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis. [PDF]

Cureus
Ahmad F, Hussain T, Gunaratne CH, Collum J, Ghaffar A, Gharbia K.   +5 more
europepmc   +1 more source

ODF3B Promotes the Progression of Clear Cell Renal Cell Carcinoma via the JAK/STAT Signaling Pathway. [PDF]

Med Sci Monit
Yun Y, Ji X, Wu T, Liu Y, Li Z, Sun Z, Zhou P, Yang L, Yu W.   +8 more
europepmc   +1 more source

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E. Myers, Pinaki Biswas, Irene Hernández‐Martín, Erman Güler, Marina Mikheil, Raj Chovatiya   +10 more
wiley   +1 more source

The role of JAK3 and TEC family kinases in vitiligo pathogenesis. [PDF]

Front Immunol
Passeron T, Seneschal J, Picardo M, Xiang L, Tanemura A, Winkler A, Telliez JB, Adiri R.   +7 more
europepmc   +1 more source